(¿Â¶óÀÎ) 2021 ´ëÇÑÇ÷¾×ÇÐȸ ±¹Á¦Çмú´ëȸ(ICKSH 2021)-4¿ù 2ÀÏ : 2021-04-02 |
|
(¿Â¶óÀÎ) 2021 ´ëÇÑÇ÷¾×ÇÐȸ ±¹Á¦Çмú´ëȸ(ICKSH 2021)-4¿ù 2ÀÏ : 2021-04-02 ±³À°ÀÏÀÚ : 2021-04-02 ±³À°Àå¼Ò : ¿Â¶óÀÎ ±³À° ±³À°ÁÖÁ¦ : (¿Â¶óÀÎ) 2021 ´ëÇÑÇ÷¾×ÇÐȸ ±¹Á¦Çмú´ëȸ(ICKSH 2021)-4¿ù 2ÀÏ ÁÖÃÖ±â°ü : ´ëÇÑÇ÷¾×ÇÐȸ ´ã´çÀÚ : À±ÁöÇý ¿¬¶ôó : 02-566-6031 À̸ÞÀÏ : hematology@kams.or.kr ±³À°Á¾·ù : ³»°ú, ¼Ò¾Æû¼Ò³â°ú, Áø´Ü°Ë»çÀÇÇаú Âü¼®¿¹»óÀοø : 500¸í Èñ¸ÁÆòÁ¡ : 6Á¡ Áö¿ª : ¼¿ïƯº°½Ã ±³À°½Ã°£ : 7 ½Ã°£ 40ºÐ ¼¼ºÎ¼ö°·á : 150,000¿ø ºñ°í ´ëÇÑÇ÷¾×ÇÐȸ ȸ¿ø £Ü50,000, Æç·Î¿ì/°£È£»ç/¿¬±¸¿ø £Ü30,000 Çлý/Àü°øÀÇ £Ü20,000, ºñȸ¿ø £Ü150,000 ±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ ±³À°½Ã°£ 04¿ù 02ÀÏ Room 3 09:00~09:30 B-Cell Lymphoma''s New Genomics °í¿µÀÏ(¼¿ïÀÇ´ë) ±³À°½Ã°£ 04¿ù 02ÀÏ Room 3 09:30~10:00 Immuno-Oncology for B-Cell Lymphomas ÃÖÀ±¼®(¾ÆÁÖÀÇ´ë) ±³À°½Ã°£ 04¿ù 02ÀÏ Room 3 10:00~10:30 Novel Combination Immunochemotherapy beyond CD20 ÀÌÁØÈ£(°í·ÁÀÇ´ë) ±³À°½Ã°£ 04¿ù 02ÀÏ Room 3 10:30~11:15 Genetic Landscape of Lymphoma and Novel Treatment Approaches Wyndham Hopkins Wilson(National Cancer Institute USA) ±³À°½Ã°£ 04¿ù 02ÀÏ Room 3 11:30~12:10 When and How to Treat Front-Line Chronic Lymphocytic Leukemia? Susan O¡¯Brien(University of Cambridge USA) ±³À°½Ã°£ 04¿ù 02ÀÏ Room 3 12:40~13:40 Adaptive natural killer cells facilitate effector functions of daratumumab in multiple myeloma Á¶Çö¼ö(¿¬¼¼ÀÇ´ë) ±³À°½Ã°£ 04¿ù 02ÀÏ Room 1 13:55~14:40 The Evolution of Acute Leukemia Diagnostics and Its Place in Treatment Elizabeth Macintyre(The Hôpital Necker-Enfants Malades France) ±³À°½Ã°£ 04¿ù 02ÀÏ Room 1 14:40~15:10 Outcome of Autologous Transplant in T-Cell Lymphoma: Experience of NIHBT in Vietnam Nguyen Vu Bao Anh(Hanoi Medical University Vietnam) ±³À°½Ã°£ 04¿ù 02ÀÏ Room 1 15:10~15:40 Subcutaneous Panniculitis-like T-Cell Lymphoma Udomsak Bunworasate(King Chulalongkorn Memorial Hospital Thailand) ±³À°½Ã°£ 04¿ù 02ÀÏ Room 1 15:40~16:10 Update of Extranodal NK/T-cell Lymphoma: Treatment and Biology ±è¼®Áø(¼º±Õ°üÀÇ´ë) ±³À°½Ã°£ 04¿ù 02ÀÏ Room 1 16:25~16:45 Immunotherapy in AML: From alloSCT towards CAR-T Cell Therapy Charles Craddock(Queen Elizabeth Hospital UK) ±³À°½Ã°£ 04¿ù 02ÀÏ Room 1 16:45~17:05 The Emerging Role of MRD in AML Gert Ossenkoppele(Amsterdam University The Netherlands) ±³À°½Ã°£ 04¿ù 02ÀÏ Room 1 17:05~17:30 Therapeutic Potential of ATO to Overcome Resistance of Bcl-2 Inhibitor in AML ÀåÁöÀº(¿¬¼¼ÀÇ´ë) ±³À°½Ã°£ 04¿ù 02ÀÏ Room 1 17:30~17:55 MRD in AML Á¶º´½Ä(°¡Å縯ÀÇ´ë) |
Tip. ±³À°ÀÏÁ¤Àº ±³À°±â°üÀÇ »çÁ¤¿¡ µû¶ó º¯°æµÉ ¼ö ÀÖÀ¸¹Ç·Î »çÀü¿¡ ¹Ýµå½Ã ±³À°±â°üÀ¸·Î ¹®ÀÇÇÏ¿© È®ÀÎ ¹Ù¶ø´Ï´Ù. |
|